News & Views | Published:


Immunotherapy for glioblastoma: quo vadis?

Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 1, 15017 (2015).

  2. 2.

    Weller, M. et al. EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315–e329 (2017).

  3. 3.

    Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

  4. 4.

    Reardon, D. A. et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab versus bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol. 19, iii21 (2017).

  5. 5.

    Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).

  6. 6.

    Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. (2019).

  7. 7.

    Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. (2019).

  8. 8.

    Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. (2019).

  9. 9.

    Weller, M. Where does O6-methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? Cancer 124, 1316–1318 (2018).

  10. 10.

    Weiss, T. et al. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. Clin. Cancer Res. 24, 882–895 (2018).

Download references

Author information

Competing interests

M.W. has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche and honoraria for lectures, participation in advisory boards and/or consultancy from Abbvie, Basilea, Bristol-Myers Squibb, Celgene, MSD, Merck (EMD), Novocure, Orbus, Roche and Tocagen. E.L.R. has received research grants Amgen, Mundipharma; honoraria for lectures or participation in advisory boards for Abbvie, Daiichi-Sankyo and Novartis.

Correspondence to Michael Weller.

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading